hGH fragment comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2026-06-30. Numbers and descriptions here follow the published literature rather than marketing material.
A central uncertainty is whether observed metabolic changes translate into meaningful clinical benefits. Study designs vary in dose, duration, and participant characteristics, making comparisons difficult. Independent replication is limited, and the field lacks consensus on optimal endpoints or treatment duration. Ongoing or future studies may clarify mechanism and effect size, but current evidence does not establish a clear therapeutic role. Researchers often call for larger, longer, and better-controlled trials, while questions remain about which patient groups might respond.
Proposed mechanism focuses on lipolysis, the breakdown of stored triglycerides into free fatty acids and glycerol. AOD-9604 is thought to act on adipose tissue without stimulating appetite or affecting blood sugar in the same way as growth hormone. Laboratory studies report increased fat oxidation in some models. The precise receptor interactions and signaling pathways remain incompletely characterized. Researchers have proposed that the peptide may influence fat mobilization through pathways distinct from the full hormone.
Research has examined whether the peptide affects fat mass independently of growth hormone's other actions. Early animal studies suggested reductions in body fat, but species differences and small sample sizes limit interpretation. Human studies have generally been short and have not consistently shown large effects. Some trials measured body composition, lipid profiles, and safety parameters, but the overall picture is one of suggestive yet inconclusive metabolic activity. Findings vary across study populations and protocols.
In laboratory settings, AOD-9604 is commonly supplied as a lyophilized powder and stored cold to limit degradation. Reconstituted solutions are typically kept refrigerated or frozen, depending on the buffer and concentration, and protected from repeated freeze-thaw cycles. Stability can be influenced by pH, temperature, and the presence of proteases. Purity is usually assessed by high-performance liquid chromatography and mass spectrometry. These practices support reproducibility, but they do not imply safety or efficacy for any human use.
Regulatory status: AOD-9604 is not approved as a therapeutic drug in the United States, European Union, or other major markets. It is listed by the World Anti-Doping Agency as a prohibited substance in sport, specifically under growth hormone fragments. Many jurisdictions restrict its sale for human consumption. Products marketed online may not meet pharmaceutical quality standards. The legal status varies by country and often depends on whether the material is presented as a research chemical, supplement, or drug.
Detection and characterization of AOD-9604 in research and anti-doping settings typically rely on mass spectrometry coupled with liquid chromatography. These methods can identify the peptide by its mass and fragmentation pattern. Immunoassays may also be used in some screening contexts, but they can cross-react with related peptides. Because the molecule is small and may be present at low concentrations, sample preparation and method validation are important. Confirmatory analysis usually requires comparison with a certified reference standard.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic peptide fragment | Not a full hormone |
| Molecular target | Proposed adipose tissue lipolysis | Receptor details uncertain |
| Typical research dose | Not established for clinical use | Doses vary across studies |
| Stability in solution | Limited; store cold | Avoid repeated freeze-thaw |
| Regulatory status | Not approved as a drug | Varies by country |
Clinical development of AOD-9604 included trials in people with obesity. Reports from early-phase and mid-phase studies described modest or inconsistent changes in body weight. A phase IIb program did not meet its primary endpoint, and the compound was not approved for medical use. Differences in formulation, delivery route, and participant characteristics may explain some of the variation. Later investigations explored whether the peptide might have effects in other tissues, including cartilage.
Regulatory treatment of AOD-9604 is shaped by its classification as a peptide hormone. The World Anti-Doping Agency lists it as a prohibited substance, and many national anti-doping organizations adopt that list. It does not hold approval as a prescription medicine in the United States, the European Union, or other major markets. Products sold online are frequently labeled for research use only and may not undergo independent quality testing. Import and possession rules differ by country, so legal status depends on local law.
Proposed mechanisms for AOD-9604 focus on fat cells. Laboratory studies suggest the peptide can increase lipolysis, the breakdown of stored fat, and reduce lipogenesis, the formation of new fat. Unlike full human growth hormone, it does not appear to stimulate substantial IGF-1 production in the studies reported so far. Some evidence points to beta-adrenergic signaling, but the precise receptor targets and downstream pathways remain unresolved. The fragment is not thought to act through the classical growth hormone receptor.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
Analytical characterization of AOD-9604 typically employs reversed-phase high-performance liquid chromatography (RP-HPLC) to assess purity and identity. Mass spectrometry provides confirmation of molecular mass, while amino acid analysis can verify composition. These methods are standard for peptide research chemicals. Because the peptide lacks a distinct chromophore, detection often relies on ultraviolet absorbance at 214 nm or mass spectrometric response. Laboratories may also use capillary electrophoresis for separation. For example, size-exclusion chromatography can detect aggregates.
Stability of AOD-9604 depends on storage conditions. Lyophilized powder is generally more stable than reconstituted solution. Recommended storage is typically at -20°C or lower, protected from light and moisture. Repeated freeze-thaw cycles can cause aggregation or degradation. In solution, the peptide may be susceptible to hydrolysis or oxidation, so aliquoting and cold storage are common practices. Researchers often add stabilizers such as mannitol or trehalose during lyophilization to improve shelf life.
Quality control for AOD-9604 involves verifying identity, purity, and concentration. Suppliers may provide a certificate of analysis listing HPLC purity and mass spectrometry data. Independent verification is advised because peptide products can vary in quality. Researchers should check for counterions, residual solvents, and microbial contamination. Proper documentation supports reproducibility and safety in laboratory studies. When sourcing, institutions often require third-party testing and detailed chain-of-custody records. These steps help ensure that experimental results are attributable to the peptide rather than impurities.
Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.
Early interest in AOD-9604 centered on whether a fragment of human growth hormone could influence fat metabolism without the broader effects of the full hormone. Cell and animal studies reported changes in fat storage and breakdown. Human trials followed, but the results were not strong enough to secure regulatory approval. The compound remains available for laboratory research, and its clinical potential is still described as uncertain. Studies continue to examine its activity and safety profile.
and hit .409 with 11 home runs, 20 walks and 1.384 OPS and collected his second consecutive Player of the Month award. He would hit another three home runs with six walks in nine August games before a pitch from Andy Benes fractured his left hand on August 10 and ended his season in the same manner the season before. Entering that game, Bagwell carried an 18-game hitting streak. Two days later, the strike ended the season for all the major leagues. His production accelerated in 26 games after the All-Star break, as he posted a .432 batting average, .530 OBP, .916 SLG, 1.446 OPS, 10 doubles, 12 home runs, 34 RBI and 30 runs scored. The Astros finished one-half game out of first place in the inaugural season of the National League Central division, a product of MLB's division realignment. Bagwell played in 110 games in the 1994 season, batting .368 with a .750 SLG, 1.201 OPS, 39 home runs, 116 RBI, 104 runs scored, 300 total bases and 213 adjusted OPS (OPS+) in 400 at bats. He led the major leagues in SLG, OPS+, RBI, and total bases, and the NL in runs scored and OPS, but fell short of winning the batting Triple Crown, finishing second for the batting title to Tony Gwynn, who, after batting .394, had the highest average in the major leagues since Ted Williams in 1941. Bagwell finished second in home runs to Matt Williams, who hit 43.
February 14 – A second shutdown affecting only the Department of Homeland Security begins. February 16 – A mass shooting occurs at the Dennis M. Lynch Arena in Pawtucket, Rhode Island, during a high school ice hockey game. The attack results in the deaths of three people, and three others hospitalized. February 17 Tributes are paid to Jesse Jackson following the announcement of the civil rights leader's death at the age of 84. Tricia McLaughlin resigns as Assistant Secretary for Public Affairs in the United States Department of Homeland Security and will leave the Trump administration amidst backlash about Trump's hardline immigration policies. An avalanche kills eight skiers northwest of Lake Tahoe in California. San Antonio Express-News publishes a story about Tony Gonzales's affair. February 19 – Trump announces he is transferring $10 billion from the US government to his "Board of Peace" which he chairs. February 20 – Legal affairs of the second Trump presidency: The U.S. Supreme Court holds in a 6–3 ruling that the IEEPA does not give the President the power to set tariffs, striking down Trump's sweeping emergency tariffs via executive orders. February 21 – Trump announces that he will increase global tariffs to 15% following the Supreme Court decision the previous day, effective from February 24. February 22 – A 21-year-old man is shot and killed after entering the secure perimeter of Trump's Mar-a-Lago residence. The suspect is described as a white male carrying a shotgun and fuel can.
Argon is used to displace oxygen- and moisture-containing air in packaging material to extend the shelf-lives of the contents (argon has the European food additive code E938). Aerial oxidation, hydrolysis, and other chemical reactions that degrade the products are retarded or prevented entirely. High-purity chemicals and pharmaceuticals are sometimes packed and sealed in argon. In winemaking, argon is used in a variety of activities to provide a barrier against oxygen at the liquid surface, which can spoil wine by fueling both microbial metabolism (as with acetic acid bacteria) and standard redox chemistry. Argon is sometimes used as the propellant in aerosol cans. Argon is also used as a preservative for such products as varnish, polyurethane, and paint, by displacing air to prepare a container for storage. Since 2002, the American National Archives stores important national documents such as the Declaration of Independence and the Constitution within argon-filled cases to inhibit their degradation. Argon is preferable to the helium that had been used in the preceding five decades, because helium gas escapes through the intermolecular pores in most containers and must be regularly replaced.
=== Agonists === 2-Chloro-N(6)-cyclopentyladenosine (CCPA). N6-Cyclopentyladenosine N(6)-cyclohexyladenosine Tecadenoson ((2R,3S,4R)-2-(hydroxymethyl)-5-(6- ((R)-tetrahydrofuran-3-ylamino)-9H-purin-9-yl)-tetrashydrofuran3,4-diol)
In symbolic terms, he was seen as signifying parliamentary control over the Army. Issues of strategic policy during wartime were managed by the Northern and Southern Departments (the predecessors of today's Foreign Office and Home Office). From 1704 to 1855 the post of Secretary remained occupied by a minister of the second rank (although he was occasionally part of the Cabinet after 1794). Many of his responsibilities were transferred to the Secretary of State for War after the creation of that more senior post in 1794 (though the latter was also responsible for Britain's colonies from 1801, and renamed Secretary of State for War and the Colonies, an arrangement which only ceased with the establishment of the Colonial Office in 1854). From 1824 the British Empire (excepting India, which was administered separately by the East India Company and then the India Office) was divided by the War and Colonial Office into the following administrative departments: North America
Sources: en.wikipedia.org
== Production == Crushed minerals are attacked by hydrochloric or sulfuric acid that transforms insoluble rare-earth oxides into soluble chlorides or sulfates. The acidic filtrates are partially neutralized with caustic soda (sodium hydroxide) to pH 3–4. Thorium precipitates out of solution as hydroxide and is removed. After that the solution is treated with ammonium oxalate to convert rare earths into their insoluble oxalates. The oxalates are converted to oxides by annealing. The oxides are dissolved in nitric acid that excludes one of the main components, cerium, whose oxide is insoluble in HNO3. The solution is treated with magnesium nitrate to produce a crystallized mixture of double salts of rare-earth metals. The salts are separated by ion exchange. In this process, rare-earth ions are sorbed onto suitable ion-exchange resin by exchange with hydrogen, ammonium or cupric ions present in the resin. The rare earth ions are then selectively washed out by suitable complexing agent. Erbium metal is obtained from its oxide or salts by heating with calcium at 1450 °C under argon atmosphere.
The South African Defence Force (SADF) (Afrikaans: Suid-Afrikaanse Weermag) comprised the armed forces of South Africa from 1957 until 1994. Shortly before the state reconstituted itself as a republic in 1961, the former Union Defence Force was officially succeeded by the SADF, which was established by the Defence Act (No. 44) of 1957. The SADF, in turn, was superseded by the South African National Defence Force in 1994.
Reef-building corals are well-studied holobionts that include the coral itself together with its symbiont zooxanthellae (photosynthetic dinoflagellates), as well as its associated bacteria and viruses. Co-evolutionary patterns exist for coral microbial communities and coral phylogeny. It is known that the coral's microbiome and symbiont influence host health, however, the historic influence of each member on others is not well understood. Scleractinian corals have been diversifying for longer than many other symbiotic systems, and their microbiomes are known to be partially species-specific. It has been suggested that Endozoicomonas, a commonly highly abundant bacterium in corals, has exhibited codiversification with its host. This hints at an intricate set of relationships between the members of the coral holobiont that have been developing as evolution of these members occurs. A study published in 2018 revealed evidence of phylosymbiosis between corals and their tissue and skeleton microbiomes. The coral skeleton, which represents the most diverse of the three coral microbiomes, showed the strongest evidence of phylosymbiosis. Coral microbiome composition and richness were found to reflect coral phylogeny. For example, interactions between bacterial and eukaryotic coral phylogeny influence the abundance of Endozoicomonas, a highly abundant bacterium in the coral holobiont. However, host-microbial cophylogeny appears to influence only a subset of coral-associated bacteria.
PRRT radiopharmaceuticals are constructed with three components; the radionuclide, chelator, and somatostatin analogue (peptide). The radionuclide delivers the actual therapeutic effect (or emission, such as photons, for imaging). The chelator is the essential link between the radionuclide and peptide. For 177Lu and 90Y this is typically DOTA (tetracarboxylic acid, and its variants) and DTPA (pentetic acid) for 111In. Other chelators known as NOTA (triazacyclononane triacetic acid) and HYNIC (hydrazinonicotinamide) have also been experimented with, albeit more for imaging applications. The somatostatin analogue affects biodistribution of the radionuclide, and therefore how effectively any treatment effect can be targeted. Changes affect which somatostatin receptor is most strongly targeted. For example, DOTA-lanreotide (DOTALAN) has a lower affinity for receptor 2 and a higher affinity for receptor 5 compared to DOTA-octreotide (DOTATOC).
Sources: en.wikipedia.org
Actoprotectors, or synthetic adaptogens, are compounds that enhance an organism's resilience to physical stress without increasing heat output. Actoprotectors are distinct from other doping compounds in that they increase physical and psychological resilience via non-exhaustive action. Actoprotectors such as bemethyl and bromantane have been used to prepare athletes and enhance performance in Olympic competition. However, only bromantane has been placed on the World Anti-Doping Agency's banned list.
=== First descriptions === In 1797, John Rollo reported on the results of treating two diabetic Army officers with a low-carbohydrate diet and medications. A very low-carbohydrate diet was the standard treatment for diabetes throughout the nineteenth century. In 1825, Jean Brillat-Savarin promoted a low-carb diet in his book, The Physiology of Taste. In 1863, William Banting, a formerly obese English undertaker and coffin maker, published "Letter on Corpulence Addressed to the Public", in which he described a diet for weight control giving up bread, butter, milk, sugar, beer, and potatoes. His booklet was widely read, so much so that some people used the term "Banting" for the activity now called "dieting". Physicians who advocated a low-carbohydrate diet consisting of large amounts of animal fat and protein to treat diabetes in the late 1800s include James Lomax Bardsley, Apollinaire Bouchardat and Frederick William Pavy. Arnaldo Cantani isolated his diabetic patients in locked rooms and prescribed them an exclusive animal-based diet. In the early 1900s Frederick Madison Allen developed a highly restrictive short term regime which was described by Walter R. Steiner at the 1916 annual convention of the Connecticut State Medical Society as The Starvation Treatment of Diabetes Mellitus. This diet was often administered in a hospital in order to better ensure compliance and safety.
After a diplomatic crisis started between Venezuela and Guyana (both Brazilian neighbours) in October 2023, President Lula tried to mediate a de-escalation while stating that "we do not want and we do not need a war in South America". Officials from Brazil, along with those from the CARICOM, Colombia, the United Nations and the CELAC attended a meeting between Venezuelan and Guyanese presidents in December 2023 to ease tensions between the nations. Brazil offered to host further talks to promote peace in the region, which was agreed by the two countries, and a meeting between Venezuelan and Guyanese Foreign Ministers took place on 25 January 2024, with both parties pledging to keep the peace and hold further talks.
Sources: en.wikipedia.org
It is proposed to promote lipolysis in fat tissue, the breakdown of stored fat into fatty acids and glycerol. The detailed receptor and signaling mechanisms are not fully established.
Because it is a fragment rather than full growth hormone, it is generally described as lacking growth-promoting effects. Some studies suggest it may influence fat metabolism without the same systemic growth effects, though evidence is limited.
Human trials have measured body weight, fat mass, lean mass, lipid levels, and adverse events. Most have been small or short-term, so conclusions about long-term outcomes are limited.
No major regulatory agency has approved AOD-9604 as a medicine. It is treated as an experimental peptide in research settings. Some countries restrict its sale or import.